tradingkey.logo

Nuwellis Inc

NUWE

0.312USD

-0.002-0.70%
Horário de mercado ETCotações atrasadas em 15 min
1.37MValor de mercado
PerdaP/L TTM

Nuwellis Inc

0.312

-0.002-0.70%
Mais detalhes de Nuwellis Inc Empresa
Nuwellis, Inc. is a commercial-stage medical technology company. The Company is focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems (collectively the Aquadex System). The Aquadex SmartFlow system is indicated for temporary or extended use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics. The Aquadex System is designed to remove excess fluid from patients suffering from fluid overload who have failed diuretic therapy. The Aquadex System consists of a console, which is a piece of equipment containing electromechanical pumps and a liquid crystal display (LCD) screen; a one-time disposable blood circuit set, which is an integrated collection of tubing, filters, sensors, and connectors that contain and deliver the blood from and back to the patient, and a disposable catheter.
Informações da empresa
Código da empresaNUWE
Nome da EmpresaNuwellis Inc
Data de listagemFeb 16, 2012
Fundado em2002
CEOErb (John L)
Número de funcionários38
Tipo de títulosOrdinary Share
Fim do ano fiscalFeb 16
Endereço12988 Valley View Rd
CidadeEDEN PRAIRIE
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal55344
Telefone19523454200
Sitehttps://www.nuwellis.com/
Código da empresaNUWE
Data de listagemFeb 16, 2012
Fundado em2002
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Archelle (Feldshon) Georgiou, M.D.
Dr. Archelle (Feldshon) Georgiou, M.D.
Independent Director
Independent Director
324.00
--
Mr. David Alan (Dave) Mcdonald
Mr. David Alan (Dave) Mcdonald
Independent Director
Independent Director
324.00
--
Mr. Gregory D. (Greg) Waller
Mr. Gregory D. (Greg) Waller
Independent Director
Independent Director
--
--
Mr. Robert B. (Rob) Scott
Mr. Robert B. (Rob) Scott
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Neil P. Ayotte, Esq.
Mr. Neil P. Ayotte, Esq.
Senior Vice President, General Counsel, Secretary and Chief Compliance Officer
Senior Vice President, General Counsel, Secretary and Chief Compliance Officer
--
--
Dr. Maria Rosa Costanzo, M.D.
Dr. Maria Rosa Costanzo, M.D.
Independent Director
Independent Director
--
--
Erb (John L)
Erb (John L)
Chairman of the Board, Interim President and Chief Executive Officer
Chairman of the Board, Interim President and Chief Executive Officer
--
--
Mr. Michael (Mike) Mccormick
Mr. Michael (Mike) Mccormick
Lead Independent Director
Lead Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Archelle (Feldshon) Georgiou, M.D.
Dr. Archelle (Feldshon) Georgiou, M.D.
Independent Director
Independent Director
324.00
--
Mr. David Alan (Dave) Mcdonald
Mr. David Alan (Dave) Mcdonald
Independent Director
Independent Director
324.00
--
Mr. Gregory D. (Greg) Waller
Mr. Gregory D. (Greg) Waller
Independent Director
Independent Director
--
--
Mr. Robert B. (Rob) Scott
Mr. Robert B. (Rob) Scott
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Neil P. Ayotte, Esq.
Mr. Neil P. Ayotte, Esq.
Senior Vice President, General Counsel, Secretary and Chief Compliance Officer
Senior Vice President, General Counsel, Secretary and Chief Compliance Officer
--
--
Dr. Maria Rosa Costanzo, M.D.
Dr. Maria Rosa Costanzo, M.D.
Independent Director
Independent Director
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: há 14 horas
Atualizado em: há 14 horas
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Erb (John L)
23.01%
Geode Capital Management, L.L.C.
0.78%
Virtu Americas LLC
0.62%
Citadel Advisors LLC
0.45%
Two Sigma Investments, LP
0.42%
Other
74.72%
Investidores
Investidores
Proporção
Erb (John L)
23.01%
Geode Capital Management, L.L.C.
0.78%
Virtu Americas LLC
0.62%
Citadel Advisors LLC
0.45%
Two Sigma Investments, LP
0.42%
Other
74.72%
Tipos de investidores
Investidores
Proporção
Hedge Fund
1.01%
Investment Advisor/Hedge Fund
0.83%
Research Firm
0.63%
Venture Capital
0.37%
Investment Advisor
0.32%
Other
96.85%
Participação acionária institucional
Atualizado em: ter, 4 de mar
Atualizado em: ter, 4 de mar
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q1
26
102.06K
2.33%
+29.99K
2024Q4
25
113.78K
2.60%
+73.44K
2024Q3
29
65.32K
2.68%
+45.76K
2024Q2
28
42.02K
3.15%
+30.15K
2024Q1
26
9.25K
4.91%
+1.97K
2023Q4
26
6.22K
6.75%
+3.61K
2023Q3
35
1.28K
4.82%
-1.76K
2023Q2
36
1.31K
5.00%
-797.00
2023Q1
36
712.00
4.39%
-1.50K
2022Q4
33
629.00
6.11%
-1.05K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Geode Capital Management, L.L.C.
30.81K
0.7%
+30.81K
--
Dec 31, 2024
Virtu Americas LLC
--
0%
-2.22K
-100.00%
Jun 30, 2024
Citadel Advisors LLC
11.77K
0.27%
+11.77K
--
Dec 31, 2024
Two Sigma Investments, LP
11.31K
0.26%
-2.32K
-17.04%
Dec 31, 2024
HRT Financial LP
--
0%
-15.13K
-100.00%
Dec 31, 2024
Tower Research Capital LLC
4.77K
0.11%
-1.58K
-24.87%
Dec 31, 2024
UBS Financial Services, Inc.
23.24K
0.53%
+23.24K
--
Dec 31, 2024
The Vanguard Group, Inc.
1.43K
0.03%
--
--
Jan 31, 2025
Ver Mais
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Jun 26, 2024
Merger
35<1
Jun 26, 2024
Merger
35<1
Jun 26, 2024
Merger
35<1
Jun 26, 2024
Merger
35<1
Dec 09, 2022
Merger
100<1
Dec 09, 2022
Merger
100<1
Data
Tipo
Proporção
Jun 26, 2024
Merger
35<1
Jun 26, 2024
Merger
35<1
Jun 26, 2024
Merger
35<1
Jun 26, 2024
Merger
35<1
Dec 09, 2022
Merger
100<1
Dec 09, 2022
Merger
100<1
Dec 09, 2022
Merger
100<1
Dec 09, 2022
Merger
100<1
Oct 17, 2020
Merger
30<1
Oct 17, 2020
Merger
30<1
Ver Mais
KeyAI